MYC and mature T-cell and NK-cell non-Hodgkin lymphoma: Given the well-established role of aberrant MYC expression in PTCL pathogenesis, disease progression, and poor prognosis (36–38), targeting MYC protein stability through this combinatorial approach may represent a novel and effective therapeutic strategy.